GT Biopharma (GTBP) Return on Equity [ROE] (2017 - 2026)
GT Biopharma's Return on Equity [ROE] came in at -198.14% for Q1 2026, up 81.79 percentage points from the prior quarter.
Powered by 
Analysis
GT Biopharma (GTBP) Return on Equity [ROE] (2017 - 2026) Analysis & Trends
For FY2025, GT Biopharma's Return on Equity [ROE] was -603.64%, down 122.69 percentage points from FY2024.
- Return on Equity [ROE] has declined in each of the last three years, with a three-year change of -478.97 percentage points (FY2022 to FY2025).
- Going back by year, Return on Equity [ROE] was -480.95% in FY2024 (-345.51 pp), -135.44% in FY2023 (-10.76 pp) and -124.68% in FY2022.
- The Q1 2026 figure represents the highest quarterly Return on Equity [ROE] since Q1 2024.
- Year-over-year, Return on Equity [ROE] increased in 1 of the last four quarters, with an average year-over-year change of -99.96 percentage points.
- The fastest year-over-year change in Return on Equity [ROE] over five years came in Q4 2025 (a gain of 6259.64 percentage points), and the weakest in Q4 2024 (a drop of 6388.68 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 25.32% |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | - |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 7.21% |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 84.40% |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 21.39% |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 83.75% |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -18.38% |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 4.97% |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 22.24% |
| 10 | GT Biopharma | 9.11 Mn | 9.11 Mn | - | -198.14% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -198.14% |
| Dec 31, 2025 | -279.94% |
| Dec 31, 2024 | -6,539.58% |
| Sep 30, 2024 | -347.30% |
| Jun 30, 2024 | -232.98% |
| Mar 31, 2024 | -194.32% |
| Dec 31, 2023 | -150.90% |
| Sep 30, 2023 | -147.18% |
| Jun 30, 2023 | -162.28% |
| Mar 31, 2023 | -157.57% |
| Dec 31, 2022 | -153.55% |
| Sep 30, 2022 | -214.52% |
| Jun 30, 2022 | -124.57% |
| Mar 31, 2022 | -67.01% |
| Dec 31, 2021 | -139.65% |
| Sep 30, 2021 | 3.53% |
| Jun 30, 2021 | -9.30% |
| Jun 30, 2019 | -2,604.39% |
| Mar 31, 2019 | -2,371.69% |
| Dec 31, 2018 | -2,100.12% |
API Access
GT Biopharma Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=GTBP&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "GTBP", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=GTBP&period=max&api_key=YOUR_API_KEY");
const data = await res.json();